Combined immunotherapy in children with atopic dermatitis: rationale for application

the study considers advantages of a combination therapy in children with atopic dermatitis (AD) and a rationale for application of multiagent immunotherapy (MIT) including parenteral allergen-specific immunotherapy (PASIT) and an immunomodulator (IM). It has been found that including MIT in the combination therapy of AD for 3 years results in lessening of severity and clinical manifestations of a disease and in improving children's quality of life (QOL).